Working… Menu

E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03332589
Recruitment Status : Recruiting
First Posted : November 6, 2017
Last Update Posted : May 1, 2020
University of Arizona
Information provided by (Responsible Party):
Spirita Oncology, LLC

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 1, 2021
Estimated Study Completion Date : June 30, 2021